Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture.
暂无分享,去创建一个
J. Kelly | S. Deechongkit | J. Buxbaum | N. Reixach | Xin Jiang | J. Kelly
[1] J. Buxbaum. Diseases of protein conformation: what do in vitro experiments tell us about in vivo diseases? , 2003, Trends in biochemical sciences.
[2] Giampaolo Merlini,et al. Molecular mechanisms of amyloidosis. , 2003, The New England journal of medicine.
[3] Joleen T White,et al. D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis? , 2003, Biochemistry.
[4] Carl W. Cotman,et al. Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.
[5] J. Kelly,et al. Prevention of Transthyretin Amyloid Disease by Changing Protein Misfolding Energetics , 2003, Science.
[6] J. Kelly,et al. Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[7] A. Olofsson,et al. Only amyloidogenic intermediates of transthyretin induce apoptosis. , 2002, Biochemical and biophysical research communications.
[8] S. Müller,et al. Transthyretin fibrillogenesis entails the assembly of monomers: a molecular model for in vitro assembled transthyretin amyloid-like fibrils. , 2002, Journal of molecular biology.
[9] James C. Sacchettini,et al. Therapeutic strategies for human amyloid diseases , 2002, Nature Reviews Drug Discovery.
[10] M. Sousa,et al. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. , 2001, The American journal of pathology.
[11] J. Kelly,et al. Support for the multigenic hypothesis of amyloidosis: The binding stoichiometry of retinol-binding protein, vitamin A, and thyroid hormone influences transthyretin amyloidogenicity in vitro , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[12] J. Kelly,et al. Anion shielding of electrostatic repulsions in transthyretin modulates stability and amyloidosis: insight into the chaotrope unfolding dichotomy. , 2001, Biochemistry.
[13] H. M. Petrassi,et al. An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured. , 2001, Biochemistry.
[14] Rui M. M. Brito,et al. Tetramer Dissociation and Monomer Partial Unfolding Precedes Protofibril Formation in Amyloidogenic Transthyretin Variants* , 2001, The Journal of Biological Chemistry.
[15] M. Saraiva,et al. Review: TTR amyloidosis-structural features leading to protein aggregation and their implications on therapeutic strategies. , 2000, Journal of structural biology.
[16] James C. Sacchettini,et al. Rational design of potent human transthyretin amyloid disease inhibitors , 2000, Nature Structural Biology.
[17] C. Wurth,et al. The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions. , 1999, Biochemistry.
[18] J. Kelly,et al. Synthesis and evaluation of anthranilic acid-based transthyretin amyloid fibril inhibitors. , 1999, Bioorganic & medicinal chemistry letters.
[19] J. Kelly,et al. The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. , 1998, Current opinion in structural biology.
[20] J. Buxbaum,et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. , 1997, The New England journal of medicine.
[21] P. Westermark,et al. Characterization of intracellular amyloid fibrils in the human choroid plexus epithelial cells , 2004, Acta Neuropathologica.
[22] D. Epps,et al. Spontaneous Aggregation and Cytotoxicity of the β-Amyloid Aβ1–40: A Kinetic Model , 2003 .
[23] J. Buxbaum,et al. The genetics of the amyloidoses. , 2000, Annual review of medicine.